RACHEL BRIDGEMOHAN: Open Payments
NPI 1811240740 · BRISTOL, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,075 in 134 payments from 19 companies in 2025. Trend: 2023 $3,272 · 2024 $3,153 · 2025 $3,075
Food & beverage: $2,906Education: $169
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $486 |
| Ardelyx, Inc. | 16 | $400 |
| ABBVIE INC. | 21 | $384 |
| Janssen Biotech, Inc. | 12 | $380 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 18 | $352 |
| Gilead Sciences, Inc. | 11 | $232 |
| Madrigal Pharmaceuticals | 6 | $185 |
| Intercept Pharmaceuticals, Inc. | 5 | $114 |
| Lilly USA, LLC | 6 | $112 |
| GENZYME CORPORATION | 3 | $73 |
Products named: IBSRELA, TREMFYA, ENTYVIO, XIFAXAN, REZDIFFRA, RINVOQ, GATTEX, OCALIVA.
Industry payments across CT — which companies pay providers there.
